In Lech­leit­er's fi­nal days, Eli Lil­ly flags up­com­ing job cuts in the wake of a PhI­II im­plo­sion

Over the last 4 years Eli Lil­ly ex­ecs have in­vest­ed hun­dreds of mil­lions of dol­lars in­to its lat­est Phase III piv­otal test for solanezum­ab, con­vinced that they were on the right track for bend­ing the curve on Alzheimer’s. The pay­off would have come in the form of what some an­a­lysts some­times con­sid­er as the gold­en tick­et in biotech, con­vert­ible in­to a multi­bil­lion-dol­lar an­nu­al rev­enue slip.

But the on­ly col­or staffers may end up look­ing at now that it has flopped, yet again, is pink, as in pink slips. The com­pa­ny $LLY is be­ing a bit coy about it, but a spokesper­son told their home town news­pa­per is look­ing at lay­offs in the wake of the post mortem on so­la.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.